ClinicalTrials.gg
RecruitingNCT06087393Updated Nov 20, 2026

CONVIVO Endomicroscopy

An interventional study of CONVIVO in Brain Tumor, sponsored by Northwell Health. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Northwell Health · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.
Updated Nov 20, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Brain Neoplasms by Northwell Health — 8 open to participants now, 8 under way, 1 of them phase 3. Brain Neoplasms · Northwell Health.

Planned enrollment
7th of 14
30 · median 30
Started
2024
the only one that year
No phase
5 of 14
4 open now
Registered
13th of 14
by date

Among the 14 studies in Brain Neoplasms by Northwell Health, this one is the 7th largest by planned enrollment, is the only one that started in 2024, is one of 5 with no phase, and was the 13th registered.

Brain Neoplasms

2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

8 of the 14 studies in Brain Neoplasms by Northwell Health are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 83 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Brain Neoplasms by Northwell Health, or all of them as a file.
02

Study summary

Visualization of the tissue microstructure during neurosurgery using a non destructive handheld imaging technology producing a real time digital image ("optical biopsy") at cellular resolution is a novel method that holds great promise for optimization and improvement of the surgical treatment of brain pathologies, brain tumors in particular. The goal of this project is to investigate and assess the ease of use of the CONVIVO FDA cleared system in discriminating healthy and abnormal tissues during in vivo use on the brain during neurosurgery in 30 patients with a working diagnosis of intrinsic brain tumors.

Read the detailed description

During surgery for the removal of brain tumors, frozen-section biopsies are routinely taken intraoperatively to help the surgeon to distinguish abnormal tissue areas from normal tissue, and to assess and guide the extent of tumor or mass resection. Frozen-section analysis is time-consuming and freezing may produce architectural artifacts in the tissue sample that are difficult to interpret. As well, some tumors are heterogeneous in cell composition, so a tissue biopsy in one area may not represent the entire tumor mass. Biopsies acquired at the border regions or margins of the surgical resection are especially crucial, because it is at those regions where decisions based on tissue analysis guide the surgeon to further extend the resection where there is more tumor tissue remaining, or halt the resection for various reasons. In practice, the number of biopsies that can be taken during surgery is limited, because the acquisition procedure is time consuming. A technology which enables intraoperative real-time visualization of tissue at cellular resolution could provide a significant advantage in defining abnormal tissue margins. Such a technology could be used to identify abnormal tissue or at a minimum could screen for the most relevant areas from which formal biopsies should be acquired. It also could help to make the process of taking biopsies more efficient, so that the total number of biopsies needed can be reduced, thus increasing positive biopsy yield. This effort is a follow-up to a previous confocal endomicroscopy in vivo study conducted at the Barrow Neurological Institute in Phoenix. Based on this work, the upgraded version of the confocal laser endomicroscopy (CONVIVO) received 510k clearance from FDA. This study aims to evaluate the learning curve associated with the intraoperative imaging of tissue microstructure and microvasculature during neurosurgical procedures using fluorescein as a contrast agent for 30 patients undergoing surgery for a working diagnosis of brain tumor. The procedure involves a small microscope (about the size of a neurosurgical suction device) which is placed gently into contact with the tissue, providing significant in vivo magnification on a scale similar to that obtained by the pathology laboratory microscope. The focus of this study will be to examine the quality of images taken from the tumor core and tumor margin, and assess the time required for both neurosurgeon and pathologist to agree on a good image. A good image is clear, has well-defined structures, very few artifacts, and is comparable to a standard frozen section biopsy in its diagnostic potential.

03

Conditions studied

  • Brain Tumor

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • . The patient is suffering from an intracranial lesion requiring surgery:
  • Patients undergoing neurosurgical resection for intrinsic presumably high grade, invasive tumors.
  • Patients undergoing neurosurgical resection for other brain tumors,.
  • All patient groups will only be comprised of elective surgical patients who have signed the prior to use

Exclusion criteria

Exclusion Criteria:

  • History of to fluorescein
  • History of allergy or bronchial asthma
  • Renal failure - Children (patients less than 18 years of age)
  • Pregnant women
  • Breast feeding women
  • Patients with inability to give
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Other
    Convivo device group

    the Convivo device will be used for all subjects enrolled in the study

    Device: CONVIVO

Interventions

  • DeviceCONVIVO

    Any clinical adverse event (AE), laboratory abnormality, or other medical condition or situation occurs such that continued participation in the study would not be in the best interest of the participant. The participant meets an exclusion criterion (either newly developed or not previously recognized) that precludes further study participation.

06

What researchers measure

Primary outcomes

  1. Investigate ease of CONVIVO.

    The outcome is to investigate and assess the ease of use of the CONVIVO FDA cleared system in discriminating healthy and abnormal tissues during in vivo use on the brain during neurosurgery in 30 patients with a working diagnosis of intrinsic brain tumors.

    Time frame: one year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Acerbi, F., Pollo, B., De Laurentis, C., Restelli, F., Falco, J., Vetrano, I. G., ... & DiMeco, F. (2020). Ex Vivo Fluorescein-Assisted Confocal Laser Endomicroscopy (CONVIVO® System) in Patients With Glioblastoma: Results From a Prospective Study. Frontiers in Oncology, 10. Belykh, E., Miller, E. J., Patel, A. A., Yazdanabadi, M. I., Martirosyan, N. L., Yağmurlu, K., ... & Preul, M. C. (2018). Diagnostic accuracy of a confocal laser endomicroscope for in vivo differentiation between normal injured and tumor tissue during fluorescein-guided glioma resection. World neurosurgery, 115, e337-e348
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Oct 2028, 56 months after the start.

Of 310 non-industry interventional studies with no phase under Brain Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 126. This study's planned 56 months is below that.

Counting every sponsor, half of 321 studies reached it within 64 months; a quarter within 35 and three quarters within 125.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion Oct 2026 → Oct 2028 and completion Oct 2026 → Aug 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2023
First posted
Oct 17, 2023
StartActual
Jan 8, 2024
Primary completionEst.
Oct 1, 2028was Oct 2026
CompletionEst.
Aug 1, 2029was Oct 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 12, 2026→Oct 1, 2028
Nov 20, 2026
Study completion
Oct 12, 2026→Aug 1, 2029
Nov 20, 2026
Interventions
Arms or interventions changed
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Primary completion Oct 12, 2026→Oct 1, 2028
    Study completion Oct 12, 2026→Aug 1, 2029
    Interventions Arms or interventions changed
    + 3 other changes: responsible party, design details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06087393
Lead sponsor
Northwell Health
Responsible party
Michael Schulder (M.D., Northwell Health) — Principal investigator
First posted
Oct 17, 2023
Start date
Jan 8, 2024
Primary completion
Oct 1, 2028 (estimated)
Completion
Aug 1, 2029 (estimated)
Last update
Nov 20, 2026

Study contacts

Betsy Moclair
Contact
bmoclair@northwell.edu
5162537753

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion